As of 2 May, 2017, the PharmaLex Group, a leading specialist provider of development consulting and scientific affairs, regulatory affairs and pharmacovigilance, has completed the merger of Complya Consulting Group.
Complya was founded in 2007 by Jonathan Morse and is based in Boston (MA, USA). Their main area of expertise is US FDA GXP Quality Assurance services.
Alongside this, Complya also provides a spectrum of related consulting services, including GCP/GLP/GMP Quality Assurance and Regulatory Affairs support.
These services complement the extensive PharmaLex service portfolio. Complya has a US and international client base of innovative start-up organisations through to major pharmaceutical companies.
Following this acquisition, and together with the most recent acquisitions of Safis Solution and The Degge Group, the PharmaLex Group now has one the largest US pool of experts supporting pharmaceutical and biotech companies with their health authority obligations.
“The merger enables PharmaLex to build on its existing US FDA Quality and Compliance expertise,” explained Dr Thomas Dobmeyer, CEO PharmaLex.
Dr Tilo Netzer, CEO PharmaLex, added: “The ability to enhance our Quality and Compliance service capabilities will help to position us as a key provider within the US market. We can now provide the complete spectrum of services to support the requirements of health authorities in all mature markets – from regulatory strategy to quality assurance services.”
“By joining the PharmaLex Group, Complya is now even better positioned to serve clients in new markets and locations, and to provide valuable new services to our existing clients in Boston and internationally,” said Jonathan Morse, CEO, Complya Consulting.
The PharmaLex Group now has more than 650 employees, with 25 offices in 12 countries and more than 650 satisfied clients worldwide.